Zenas BioPharma, Inc.
NASDAQ Global SelectTotal Valuation
Zenas BioPharma, Inc. carries a market capitalization of 776.79M, placing it among publicly traded companies globally. Its enterprise value stands at 491.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 776.79M |
| Enterprise Value | 491.20M |
Share Statistics
Zenas BioPharma, Inc. currently has 62.38M shares outstanding.
| Shares Outstanding | 62.38M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.11 |
| P/TBV Ratio | 2.80 |
| P/FCF Ratio | -5.22 |
| P/OCF Ratio | -4.47 |
Financial Position
Zenas BioPharma, Inc. maintains a current ratio of 11.94, meaning it holds 11.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.45, indicating elevated leverage, while an interest coverage ratio of -37.91 demonstrates limited ability to service its debt obligations.
| Current Ratio | 11.94 |
| Quick Ratio | 11.73 |
| Debt / Equity | 79.45 |
| Debt / EBITDA | -1.06 |
| Interest Coverage | -37.91 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -78.63 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 126,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Zenas BioPharma, Inc.'s stock has gained approximately 82.77311% over the past 52 weeks. The 50-day moving average sits at 19.80, while the 200-day moving average is 24.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | 82.77311% |
| 50-Day Moving Average | 19.80 |
| 200-Day Moving Average | 24.59 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -251.37M, while operating income came in at -251.40M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -251.40M |
| Pretax Income | -425.02M |
| Net Income | -425.15M |
| EBITDA | -251.37M |
| EBIT | -251.40M |
| Earnings Per Share (EPS) | -8.83 |
Balance Sheet
Zenas BioPharma, Inc. holds 717.21M in cash and equivalents against 266.83M in total debt, resulting in a net debt position of -234.51M. Total book value stands at -846.11M, with working capital of 669.00M providing operational flexibility.
| Cash & Cash Equivalents | 717.21M |
| Total Debt | 266.83M |
| Net Debt | -234.51M |
| Equity (Book Value) | -846.11M |
| Book Value Per Share | -17.57 |
| Working Capital | 669.00M |
Cash Flow
Zenas BioPharma, Inc. produced -210.48M in operating cash flow over the past twelve months. After subtracting -30.00M in capital expenditures, free cash flow totaled -240.48M - equivalent to -4.99 per share.
| Operating Cash Flow | -210.48M |
| Capital Expenditures | -30.00M |
| Free Cash Flow | -240.48M |
| FCF Per Share | -4.99 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -68.89 |
| FCF Yield | -19.17 |
Scores
Zenas BioPharma, Inc. posts an Altman Z-Score of -0.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.25 |